Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
Abstract Background Myasthenia gravis (MG) is an autoimmune disease predominantly driven by autoantibodies targeting acetylcholine receptor (AChR), resulting in muscle weakness. Efgartigimod, a neonatal Fc receptor (FcRn) blocker, reduces pathogenic immunoglobulin G in anti‐AChR antibody‐positive ge...
Saved in:
| Main Authors: | Hui‐Ning Li, Jingjing Liu, Xiao‐Yu Huang, Lijie Zhu, Zhirui Liu, Chun‐Sheng Yang, Bo Zhang, Shixiong Huang, Fu‐Dong Shi, Zhigang Cai, Chao Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctm2.70436 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01) -
The FcRn from gene to protein and function: comparison between species
by: Luz Belinda Ortiz-Alegría, et al.
Published: (2025-08-01) -
Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies
by: SuBin Lee, et al.
Published: (2025-07-01) -
Myasthenia gravis: The evolving therapeutic landscape
by: Gil I. Wolfe, et al.
Published: (2024-12-01) -
Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients
by: Marina Mané-Damas, et al.
Published: (2025-05-01)